# Resource Summary Report

Generated by RRID on Aug 28, 2026

## MIA PaCa-2

RRID:CVCL_0428
Type: Cell Line

### Proper Citation

RRID:CVCL_0428

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_0428

**Proper Citation:** RRID:CVCL_0428

**Description:** Cell line MIA PaCa-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Pancreatic undifferentiated carcinoma

**Defining Citation:** PMID:832918, PMID:1630814, PMID:1764370, PMID:7809022, PMID:7961102, PMID:8026879, PMID:8194712, PMID:9290701, PMID:10027410, PMID:11115575, PMID:11169957, PMID:11169959, PMID:11787853, PMID:12068308, PMID:12692724, PMID:14695172, PMID:15770730, PMID:16912165, PMID:17254797, PMID:18298655, PMID:18380791, PMID:18575732, PMID:19077451, PMID:19188929, PMID:19904223, PMID:20037478, PMID:20164919, PMID:20215515, PMID:20418756, PMID:21607521, PMID:22460905, PMID:22585861, PMID:23386380, PMID:25167228, PMID:25485619, PMID:25485960, PMID:25877200, PMID:25984343, PMID:26216984, PMID:26884312, PMID:27067801, PMID:27259358, PMID:27397505, PMID:28196595, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31037374, PMID:31068700, PMID:31978347, PMID:32782605, PMID:34207840, PMID:35839778

**Comments:** Caution: Additional TP53 mutation in c.818G>A indicated incorrectly in PubMed=1630814., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** MIA PaCa-2

**Synonyms:** MIA-PaCa-2, MIA-PACA-2, MIA-Pa-Ca-2, MIA Paca2, MIA PaCa2, MiaPaCa-2, MIAPACA-2, MiaPaca.2, MiaPaCa2, Miapaca2, MIAPaCa2, MIAPACA2, Mia PACA 2, MIAPaCa-2, PaCa2, MiaPaCa, MIAMI Pancreatic Carcinoma-2

**Cross References:** BTO:BTO_0002137, CLO:CLO_0007726, CLO:CLO_0050101, EFO:EFO_0002236, MCCL:MCC:0000325, CLDB:cl3480, CLDB:cl3481, CLDB:cl3482, AddexBio:C0018002/59, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3263, ArrayExpress:E-MTAB-3610, ATCC:CRL-1420, ATCC:CRM-CRL-1420, BCRC:60139, BCRJ:0174, BioGRID_ORCS_Cell_line:544, BioSample:SAMN01821579, BioSample:SAMN01821700, BioSample:SAMN03472131, BioSample:SAMN10988205, cancercelllines:CVCL_0428, CCRID:3101HUMSCSP568, CCRID:4201HUM-CCTCC00255, CCTCC:GDC0255, Cell_Model_Passport:SIDM00505, CGH-DB:321-1, CGH-DB:9374-4, ChEMBL-Cells:CHEMBL3308500, ChEMBL-Targets:CHEMBL614725, CLS:300438, Cosmic:707249, Cosmic:710861, Cosmic:719677, Cosmic:724644, Cosmic:724870, Cosmic:730532, Cosmic:808172, Cosmic:868243, Cosmic:872996, Cosmic:913313, Cosmic:918056, Cosmic:922249, Cosmic:923170, Cosmic:932520, Cosmic:947399, Cosmic:948373, Cosmic:948731, Cosmic:949234, Cosmic:968107, Cosmic:1006368, Cosmic:1066202, Cosmic:1108337, Cosmic:1198208, Cosmic:1299302, Cosmic:1320461, Cosmic:1366278, Cosmic:1477431, Cosmic:1534318, Cosmic:1571779, Cosmic:1609545, Cosmic:1644314, Cosmic:1995507, Cosmic:2434084, Cosmic:2664042, Cosmic:2668287, Cosmic:2755950, Cosmic-CLP:724870, DepMap:ACH-000601, DSMZ:ACC-733, DSMZCellDive:ACC-733, ECACC:85062806, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10488-107B2, FCS-free:216-2-440-1-3-6, GDSC:724870, GEO:GSM206526, GEO:GSM244425, GEO:GSM621895, GEO:GSM784703, GEO:GSM887320, GEO:GSM888396, GEO:GSM1024404, GEO:GSM1374677, GEO:GSM1374678, GEO:GSM1374679, GEO:GSM1435696, GEO:GSM1435697, GEO:GSM1435698, GEO:GSM1588612, GEO:GSM1588624, GEO:GSM1670109, GEO:GSM5481591, GEO:GSM5481592, GEO:GSM5481593, GEO:GSM5481594, IARC_TP53:316, IGRhCellID:MIAPaCa, IZSLER:BS TCL 42, JCRB:JCRB0070, KCLB:21420, LiGeA:CCLE_231, LINCS_LDP:LCL-1738, Lonza:751, MetaboLights:MTBLS812, NCBI_Iran:C459, PharmacoDB:MIAPaCa2_931_2019, PRIDE:PXD001260, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_0428, PubChem_Cell_line:CVCL_0428, RCB:RCB2094, SKY/M-FISH/CGH:1996, TKG:TKG 0227, Wikidata:Q54905679

**ID:** CVCL_0428

**Record Creation Time:** 20220427T220808+0000

**Record Last Update:** 20260815T234623+0000

## Ratings and Alerts

No rating or validation information has been found for MIA PaCa-2.

No alerts have been found for MIA PaCa-2.

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 1066 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .

Treekitkarnmongkol W, et al. (2026) RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. Nature cell biology, 28(1), 197.

Sekiguchi N, et al. (2026)

Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment response

. International journal of oncology, 68(3).
Safari M, et al. (2026) Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 84, 101312.

Li G, et al. (2026) Mitochondrial VHL rewires cell metabolism in hypoxia. Cell metabolism, 38(1), 174.

Zhang Y, et al. (2026) SERPINA3 mediates liver cancer cells escape from chemotherapy-induced neutrophil extracellular trap killing. Cell reports, 45(2), 116956.

Garczyk M, et al. (2026) Targeting PI3K? suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Cell reports, 45(4), 117188.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Drouillard D, et al. (2026) Mutant KRAS promotes NF-?B driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma. bioRxiv : the preprint server for biology.

Jungwirth J, et al. (2026) The Host Cell Factor Phosphatase-2A Subunit PR130 Restricts Replication of Herpes Simplex Virus Type-1. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e23697.

Eissa IR, et al. (2026) The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. iScience, 29(7), 116500.

Álvaro BS, et al. (2026) Synthesis of Benzopyrans and Quinolines with Nitrogenated Chain and Their Cytotoxicity Against Human Cancer Cell Lines. ChemMedChem, 21(2), e202500904.

Frädrich J, et al. (2026) Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. Cell reports. Medicine, 7(1), 102546.

Anh DXT, et al. (2026) GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(14), e14735.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. Cell reports. Medicine, 7(2), 102577.

Liang X, et al. (2026) CK2-mediated HDAC5 shuttling regulates DNA end resection through Ku70 deacetylation. Theranostics, 16(7), 3648.

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and ?3?1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. Cancer research, 86(1), 99.

Hosogane M, et al. (2026) Variant-specific interaction of kinectin 1 with the multi-tRNA synthetase complex regulates ER sheet organization. iScience, 29(1), 114303.

Kaur T, et al. (2026) Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. Molecular cancer research : MCR, 24(1), 34.

Dai H, et al. (2026) 5'-NucA-SMCC-DM1 and 5'-NucA-SPDMV-DM1 are Potent Aptamer-Drug Conjugates against Pancreatic Cancer. ACS omega, 11(7), 12461.

Kong C, et al. (2026) Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. Communications biology, 9(1).